Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 18/20 | 0.59 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.54 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.54 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21756597 | 0.93 | FGFR4 (0.61) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL21386705 | 0.93 | FGFR1 (0.59) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL21756501 | 0.89 | FGFR4 (0.48) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL21756579 | 0.86 | FGFR4 (0.50) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL21756573 | 0.85 | FGFR4 (0.49) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL21756500 | 0.85 | FGFR4 (0.51) | FGFR4FGFR1FGFR2 | |
| SCHEMBL21756567 | 0.83 | FGFR4 (0.49) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL21756574 | 0.82 | FGFR4 (0.71) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL21756518 | 0.78 | FGFR4 (0.55) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL21386706 | 0.76 | FGFR4 (0.39) | FGFR4FGFR1FGFR2FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008292-B2 | FGFR4 inhibitor and preparation method and use thereof | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2021-05-18 | — | — | US | disclosed |
| US-20200062716-A1 | FGFR4 INHIBITOR AND PREPARATION METHOD AND USE THEREOF | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008292-B2 | FGFR4 inhibitor and preparation method and use thereof | FGFR4, FGFR1, FGFR2 | FGFR4 1/4885FGFR1 2/4885FGFR2 3/4885 |
| US-20200062716-A1 | FGFR4 INHIBITOR AND PREPARATION METHOD AND USE THEREOF | FGFR4, FGFR1, FGFR2 | FGFR4 1/4885FGFR1 2/4885FGFR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.